Morphic Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Morphic Medical is a private, clinical-stage medical device company pioneering a novel approach to treating type 2 diabetes and obesity. Its core technology, the RESET® therapy, is an endoscopically implanted device that aims to address the root physiological causes of these diseases, offering a potential alternative for patients underserved by drugs but not candidates for surgery. The company is currently advancing RESET® through a U.S. clinical trial (STEP-1) and is positioned to address a massive global market with significant unmet need. Morphic represents a convergence of gastroenterology and metabolic disease treatment with a minimally invasive device platform.

Metabolic DiseaseType 2 DiabetesObesity

Technology Platform

Endoscopically delivered and removable device platform designed to reconstruct/modulate the duodenal mucosa to restore metabolic function (RESET® Therapy).

Opportunities

The massive and growing global epidemic of type 2 diabetes and obesity creates a multi-billion dollar addressable market.

A significant treatment gap exists for patients who fail drug therapy but are not candidates for surgery, representing a key demographic for a minimally invasive device.

Positive clinical data could position RESET® as a new standard of care, potentially attracting partnership or acquisition interest from large medtech or pharmaceutical companies.

Risk Factors

High clinical and regulatory risk: the entire venture depends on successful trial outcomes and FDA approval for a novel mechanism.

Fierce competition from highly effective and convenient pharmaceutical therapies, particularly GLP-1 receptor agonists.

Commercialization risks include achieving physician adoption, procedural reimbursement, and demonstrating long-term durability and cost-effectiveness.

Competitive Landscape

Morphic competes in the broad type 2 diabetes/obesity market, facing direct competition from pharmaceutical giants (e.g., Novo Nordisk, Eli Lilly with GLP-1 drugs) and bariatric surgery. In the device space, it may compete with other endoscopic metabolic devices (e.g., gastric balloons, duodenal mucosal resurfacing devices) and is a pioneer in the specific niche of restorative duodenal intervention. Its key differentiator is the aim to treat the root cause via a removable, endoscopic device.

More companies in United States →